PRCT Stock: Price, Earnings History and SEC Filings
PROCEPT BioRobotics Corporation (PRCT) last traded at $19.20, down 5.42% on the latest session and up 5.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.47 against an analyst estimate of $-0.46, a miss of 2.2%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PRCT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.47 | $-0.46 | -2.17% |
| Mar 2026 | Apr 29, 2026 | $-0.56 | $-0.55 | -1.82% |
| Dec 2025 | Feb 25, 2026 | $-0.53 | $-0.32 | -65.63% |
| Sep 2025 | Nov 4, 2025 | $-0.38 | $-0.41 | +7.32% |
PRCT beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How PRCT reacts to earnings
Across its last 8 earnings releases, PRCT moved 9.2% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-04 | After close | +5.80% |
| 2026-04-29 | After close | +10.73% |
| 2026-02-25 | After close | -15.12% |
| 2025-11-04 | After close | -9.74% |
| 2025-08-06 | After close | -13.35% |
| 2025-07-24 | After close | -4.98% |
| 2025-04-24 | Before open | -5.64% |
| 2025-02-25 | After close | +8.61% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
PRCT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $308M | -$96M | -$58M | -31.0% | $-1.72 |
| 2024 | $224M | -$91M | -$104M | -40.7% | $-1.75 |
| 2023 | $136M | -$106M | -$133M | -77.8% | $-2.24 |
| 2022 | $75M | -$87M | -$83M | -116.2% | $-1.96 |
| 2021 | $34M | -$60M | -$58M | -173.6% | $-3.63 |
| 2020 | $8M | -$53M | -$49M | -687.0% | $-14.47 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for PRCT
- 8-K · Oct 2, 2026Officer or director change, Financial statements and exhibits
- 8-K · Sep 24, 2026Material agreement, Financial statements and exhibits
- 10-Q · Aug 5, 2026
- 8-K · Aug 4, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 10, 2026Shareholder vote
- 10-Q · Apr 30, 2026
- 8-K · Apr 29, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 22, 2026
- 8-K · Mar 6, 2026Officer or director change, Financial statements and exhibits
- 10-K · Feb 26, 2026
Insider filing activity
PRCT insiders filed 9 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
PRCT news
- PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Oct 28, 2026 · finance.yahoo.com
- PROCEPT BioRobotics (PRCT) Stock May Be Fully Priced On Cash Flow HopesOct 25, 2026 · finance.yahoo.com
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation (PRCT) is a US-listed public company on Nasdaq. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.